Thrivent Financial for Lutherans
IMVT icon

Thrivent Financial for Lutherans’s Immunovant IMVT Stock Holding History

Thrivent Financial for Lutherans’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-45,614
Closed -$2.11M – 2543
2020
Q4 		$2.11M Buy
+45,614
New +$2.11M ﹤0.01% 1285

Other funds holding IMVT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Thrivent Financial for Lutherans's IMVT Position: Q1 2021 in Review

Thrivent Financial for Lutherans sold out of Immunovant (IMVT) in Q1 2021, closing a stake of 45,614 shares — an estimated $2.11M sold.

Thrivent Financial for Lutherans first reported a position in IMVT in Q4 2020 and held it in 1 quarter. The position peaked at $2.11M in Q4 2020. 120 funds tracked by Wall St. Rank hold IMVT as of Q1 2021.

  • Thrivent Financial for Lutherans reported no remaining Immunovant position as of Q1 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 45,614 Immunovant shares in Q1 2021, an estimated $2.11M.
  • Thrivent Financial for Lutherans first reported a position in Immunovant in Q4 2020 and held it in 1 quarter.
  • Thrivent Financial for Lutherans's Immunovant position peaked at $2.11M in Q4 2020.
  • 120 funds tracked by Wall St. Rank held Immunovant as of Q1 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2021, filed 17 May 2021.